Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03566511 · ClinicalTrials.gov registry record · Phase 2
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide
A Phase 2 study, sponsored by Meredith Hawkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT03566511 is a Phase 2 study that was terminated before completion, run by Meredith Hawkins. The registered enrollment target is 37 participants.
The verdict
NCT03566511, a Phase 2 study, was terminated before completion, sponsored by Meredith Hawkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals. This is important since people with diabetes have inappropriately high production of glucose, which could be at least in part due to impaired activation of important brain centers.
Interventions
- DRUG Placebo
- DRUG Diazoxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-06-12 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03566511
The ClinicalTrials.gov registry entry for NCT03566511 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meredith Hawkins, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03566511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03566511 about?
NCT03566511 is a clinical study titled "Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide". The goal of this study is to determine whether metabolic control centers in the brain can be activated in patients with type 2 diabetes (T2D) as compared to non-diabetic individuals. This is important since people with diabetes have inappropriately high production of glucose, which could be at least...
What is the current status of trial NCT03566511?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2018-06-12. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT03566511?
The interventions under investigation include: Placebo (DRUG), Diazoxide (DRUG).
Who is sponsoring clinical trial NCT03566511?
This trial is sponsored by Meredith Hawkins, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.